Quarterly ResultAug 5, 2026, 06:33 AM
Zimmer Biomet Q2 Net Sales $2.177B; Raises Full-Year Guidance
AI Summary
Zimmer Biomet reported strong second-quarter 2026 financial results, with net sales increasing 4.8% to $2.177 billion and diluted earnings per share rising 33.8% to $1.03. The company also announced an increase in its share repurchase expectations to up to $1 billion for fiscal year 2026 and received FDA clearance for its next-generation ROSA® Shoulder System. Following a strong first half, Zimmer Biomet updated its full-year 2026 financial guidance, raising both revenue and adjusted EPS projections.
Key Highlights
- Q2 2026 net sales increased 4.8% to $2.177 billion.
- Q2 2026 diluted EPS rose 33.8% to $1.03; adjusted EPS was $2.07.
- Full-year 2026 reported revenue guidance raised to 3.9%-4.9%.
- Full-year 2026 adjusted diluted EPS guidance raised to $8.47-$8.59.
- Increased share repurchase expectations up to $1 billion for FY 2026.
- Received U.S. FDA 510(k) clearance for ROSA® Shoulder System.
- Q2 US sales grew 5.6% to $1,239.9 million; International sales grew 3.7% to $937.0 million.
- Q2 Technology & Data, Bone Cement and Surgical sales increased 21.1% to $199.4 million.
Price Impact
More from ZBH